Loading company…
Orbis Medicines develops macrocycle drugs and oral alternatives to biologic medicines.
Orbis Medicines uses its nGen platform to discover oral macrocycle drug candidates and offers chemical synthesis and assay services. Founded in 2021 and based in Frederiksberg, Denmark, it raised DKK 193.78 million in Seed funding in February 2024, co-led by Novo Holdings and Forbion. In January 6, 2025, it raised EUR 90 million in Series A funding led by New Enterprise Associates, with other investors participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in